Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company.

BIOVF has been the subject of a number of research reports. HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Pareto Securities cut Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $48.20 on Monday. Swedish Orphan Biovitrum has a twelve month low of $28.93 and a twelve month high of $49.03. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The company has a market cap of $17.16 billion, a PE ratio of 107.12 and a beta of 0.35. The business’s 50-day simple moving average is $48.32 and its 200 day simple moving average is $43.90.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.